Arvinas Posts 82-Cent Quarterly Loss as Profitability Fades
ARVN is trading near its 52-week low of $6.74 (12% above the low).
Summary
Arvinas reported a third-quarter loss of 82 cents per share, a swing back into the red after Q2 2026's $169.4M net profit on $249.7M of revenue tied to the VEPPANU licensing deal and milestone payments. That prior profit was driven by one-time deal economics, so the quarterly loss is a reminder the underlying business still burns cash. Third-quarter revenue was USD 500 Thousand, and research and development expenses were $46.9M. With a market cap near $492M and shares at $7.52, the loss is material relative to the company's size and keeps the cash-runway question front and center. Arvinas reported $558.9M in cash, with runway into H2 2028.
At the time of this announcement, ARVN was trading at $7.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $491.7M. The 52-week trading range was $6.74 to $14.51. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.